Top

Journal of Bone and Mineral Metabolism

Published in:

30-01-2023 | Bone Metastasis | Invited Review

Cancer–nerve interplay in cancer progression and cancer-induced bone pain

Authors: Toshiyuki Yoneda, Masahiro Hiasa, Tatsuo Okui, Kenji Hata

Published in: Journal of Bone and Mineral Metabolism | Issue 3/2023

Abstract

Introduction

Cancer-induced bone pain (CIBP) is one of the most common and debilitating complications associated with bone metastasis. Although our understanding of the precise mechanism is limited, it has been known that bone is densely innervated, and that CIBP is elicited as a consequence of increased neurogenesis, reprogramming, and axonogenesis in conjunction with sensitization and excitation of sensory nerves (SNs) in response to the noxious stimuli that are derived from the tumor microenvironment developed in bone. Recent studies have shown that the sensitized and excited nerves innervating the tumor establish intimate communications with cancer cells by releasing various tumor-stimulating factors for tumor progression.

Approaches

In this review, the role of the interactions of cancer cells and SNs in bone in the pathophysiology of CIBP will be discussed with a special focus on the role of the noxious acidic tumor microenvironment, considering that bone is in nature hypoxic, which facilitates the generation of acidic conditions by cancer. Subsequently, the role of SNs in the regulation of cancer progression in the bone will be discussed together with our recent experimental findings.

Conclusion

It is suggested that SNs may be a newly-recognized important component of the bone microenvironment that contribute to not only in the pathophysiology of CIBP but also cancer progression in bone and dissemination from bone. Suppression of the activity of bone-innervating SNs, thus, may provide unique opportunities in the treatment of cancer progression and dissemination, as well as CIBP.

Goldberg DS, McGee SJ (2011) Pain as a global public health priority. BMC Public Health 11:770. https://doi.org/10.1186/1471-2458-11-770CrossRefPubMedPubMedCentral

Swieboda P, Filip R, Prystupa A, Drozd M (2013) Assessment of pain: types, mechanism and treatment. Ann Agric Environ Med Spec 1:2–7

Falk S, Dickenson AH (2014) Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 32:1647–1654. https://doi.org/10.1200/jco.2013.51.7219CrossRefPubMed

Zylla D, Steele G, Gupta P (2017) A systematic review of the impact of pain on overall survival in patients with cancer. Support Care Cancer 25:1687–1698. https://doi.org/10.1007/s00520-017-3614-yCrossRefPubMed

Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, Guise T, Colangeli S, Capanna R, Costa L (2020) Bone metastases. Nat Rev Dis Primers 6:83. https://doi.org/10.1038/s41572-020-00216-3CrossRefPubMed

Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletalmorbidity. Clin Cancer Res 12:6243s-s6249. https://doi.org/10.1158/1078-0432.Ccr-06-0931CrossRefPubMed

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K (2013) Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer 119:832–838. https://doi.org/10.1002/cncr.27789CrossRefPubMed

Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB, Holen I (2021) Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev 101:797–855. https://doi.org/10.1152/physrev.00012.2019CrossRefPubMed

von Moos R, Costa L, Ripamonti CI, Niepel D, Santini D (2017) Improving quality of life in patients with advanced cancer: targeting metastatic bone pain. Eur J Cancer 71:80–94. https://doi.org/10.1016/j.ejca.2016.10.021CrossRef

10.

Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26:2544–2549. https://doi.org/10.1200/jco.2007.15.0367CrossRefPubMed

11.

Coveler AL, Mizrahi J, Eastman B, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S (2021) Pancreas cancer-associated pain management. Oncologist 26:e971–e982. https://doi.org/10.1002/onco.13796CrossRefPubMedPubMedCentral

12.

Patrick DL, Ferketich SL, Frame PS, Harris JJ, Hendricks CB, Levin B, Link MP, Lustig C, McLaughlin J, Ried LD, Turrisi AT 3rd, Unützer J, Vernon SW (2003) National institutes of health state-of-the-science conference statement: symptom management in cancer: pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer Inst 95:1110–1117. https://doi.org/10.1093/jnci/djg014CrossRefPubMed

13.

Staats PS, Hekmat H, Sauter P, Lillemoe K (2001) The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain Med 2:28–34. https://doi.org/10.1046/j.1526-4637.2001.002001028.xCrossRefPubMed

14.

Mantyh PW (2014) Bone cancer pain: from mechanism to therapy. Curr Opin Support Palliat Care 8:83–90. https://doi.org/10.1097/spc.0000000000000048CrossRefPubMedPubMedCentral

15.

Ivanusic JJ (2017) Molecular mechanisms that contribute to bone marrow pain. Front Neurol 8:458. https://doi.org/10.3389/fneur.2017.00458CrossRefPubMedPubMedCentral

16.

Liebig C, Ayala G, Wilks JA, Berger DH, Albo D (2009) Perineural invasion in cancer: a review of the literature. Cancer 115:3379–3391. https://doi.org/10.1002/cncr.24396CrossRefPubMed

17.

Bapat AA, Hostetter G, Von Hoff DD, Han H (2011) Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer 11:695–707. https://doi.org/10.1038/nrc3131CrossRefPubMed

18.

Ivanusic JJ (2009) Size, neurochemistry, and segmental distribution of sensory neurons innervating the rat tibia. J Comp Neurol 517:276–283. https://doi.org/10.1002/cne.22160CrossRefPubMed

19.

Jung WC, Levesque JP, Ruitenberg MJ (2017) It takes nerve to fight back: the significance of neural innervation of the bone marrow and spleen for immune function. Semin Cell Dev Biol 61:60–70. https://doi.org/10.1016/j.semcdb.2016.08.010CrossRefPubMed

20.

Brazill JM, Beeve AT, Craft CS, Ivanusic JJ, Scheller EL (2019) Nerves in bone: evolving concepts in pain and anabolism. J Bone Miner Res 34:1393–1406. https://doi.org/10.1002/jbmr.3822CrossRefPubMed

21.

Wan QQ, Qin WP, Ma YX, Shen MJ, Li J, Zhang ZB, Chen JH, Tay FR, Niu LN, Jiao K (2021) Crosstalk between Bone and Nerves within Bone. Adv Sci (Weinh) 8:2003390. https://doi.org/10.1002/advs.202003390CrossRefPubMed

22.

Cooper RR (1968) Nerves in cortical bone. Science 160:327–328. https://doi.org/10.1126/science.160.3825.327CrossRefPubMed

23.

Serre CM, Farlay D, Delmas PD, Chenu C (1999) Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone 25:623–629. https://doi.org/10.1016/s8756-3282(99)00215-xCrossRefPubMed

24.

Irie K, Hara-Irie F, Ozawa H, Yajima T (2002) Calcitonin gene-related peptide (CGRP)-containing nerve fibers in bone tissue and their involvement in bone remodeling. Microsc Res Tech 58:85–90. https://doi.org/10.1002/jemt.10122CrossRefPubMed

25.

Mach DB, Rogers SD, Sabino MC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O’Leary P, Mantyh PW (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155–166. https://doi.org/10.1016/s0306-4522(02)00165-3CrossRefPubMed

26.

Fukuda T, Takeda S, Xu R, Ochi H, Sunamura S et al (2013) Sema3A regulates bone-mass accrual through sensory innervations. Nature 497:490–493. https://doi.org/10.1038/nature12115CrossRefPubMed

27.

Julius D, Basbaum AI (2001) Molecular mechanisms of nociception. Nature 413:203–210. https://doi.org/10.1038/35093019CrossRefPubMed

28.

Chartier SR, Mitchell SAT, Majuta LA, Mantyh PW (2018) The changing sensory and sympathetic innervation of the young, adult and aging mouse femur. Neuroscience 387:178–190. https://doi.org/10.1016/j.neuroscience.2018.01.047CrossRefPubMed

29.

Hiasa M, Okui T, Allette YM, Ripsch MS, Sun-Wada GH, Wakabayashi H, Roodman GD, White FA, Yoneda T (2017) Bone pain induced by multiple myeloma is reduced by targeting V-ATPase and ASIC3. Cancer Res 77:1283–1295. https://doi.org/10.1158/0008-5472.Can-15-3545CrossRefPubMedPubMedCentral

30.

Wakabayashi H, Wakisaka S, Hiraga T, Hata K, Nishimura R, Tominaga M, Yoneda T (2018) Decreased sensory nerve excitation and bone pain associated with mouse Lewis lung cancer in TRPV1-deficient mice. J Bone Miner Metab 36:274–285. https://doi.org/10.1007/s00774-017-0842-7CrossRefPubMed

31.

Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, Frenette PS (2013) Autonomic nerve development contributes to prostate cancer progression. Science 341:1236361. https://doi.org/10.1126/science.1236361CrossRefPubMed

32.

Jobling P, Pundavela J, Oliveira SM, Roselli S, Walker MM, Hondermarck H (2015) Nerve-cancer cell cross-talk: a novel promoter of tumor progression. Cancer Res 75:1777–1781. https://doi.org/10.1158/0008-5472.Can-14-3180CrossRefPubMed

33.

Elefteriou F (2018) Impact of the autonomic nervous system on the skeleton. Physiol Rev 98:1083–1112. https://doi.org/10.1152/physrev.00014.2017CrossRefPubMedPubMedCentral

34.

Zahalka AH, Frenette PS (2020) Nerves in cancer. Nat Rev Cancer 20:143–157. https://doi.org/10.1038/s41568-019-0237-2CrossRefPubMedPubMedCentral

35.

Lorenz MR, Brazill JM, Beeve AT, Shen I, Scheller EL (2021) A neuroskeletal atlas: spatial mapping and contextualization of axon subtypes innervating the long bones of C3H and B6 mice. J Bone Miner Res 36:1012–1025. https://doi.org/10.1002/jbmr.4273CrossRefPubMed

36.

Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1–18. https://doi.org/10.1016/s0304-3959(96)03267-8CrossRefPubMed

37.

Zajączkowska R, Kocot-Kępska M, Leppert W, Wordliczek J (2019) Bone pain in cancer patients: mechanisms and current treatment. Int J Mol Sci. https://doi.org/10.3390/ijms20236047CrossRefPubMedPubMedCentral

38.

Silverman DA, Martinez VK, Dougherty PM, Myers JN, Calin GA, Amit M (2021) Cancer-associated neurogenesis and nerve-cancer cross-talk. Cancer Res 81:1431–1440. https://doi.org/10.1158/0008-5472.Can-20-2793CrossRefPubMed

39.

Okui T, Hiasa M, Ryumon S, Ono K, Kunisada Y, Ibaragi S, Sasaki A, Roodman GD, White FA, Yoneda T (2021) The HMGB1/RAGE axis induces bone pain associated with colonization of 4T1 mouse breast cancer in bone. J Bone Oncol 26:100330. https://doi.org/10.1016/j.jbo.2020.100330CrossRefPubMed

40.

Jimenez-Andrade JM, Bloom AP, Stake JI, Mantyh WG, Taylor RN, Freeman KT, Ghilardi JR, Kuskowski MA, Mantyh PW (2010) Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci 30:14649–14656. https://doi.org/10.1523/jneurosci.3300-10.2010CrossRefPubMedPubMedCentral

41.

March B, Faulkner S, Jobling P, Steigler A, Blatt A, Denham J, Hondermarck H (2020) Tumour innervation and neurosignalling in prostate cancer. Nat Rev Urol 17:119–130. https://doi.org/10.1038/s41585-019-0274-3CrossRefPubMed

42.

Maes C, Carmeliet G, Schipani E (2012) Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol 8:358–366. https://doi.org/10.1038/nrrheum.2012.36CrossRefPubMed

43.

Simon MC, Keith B (2008) The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9:285–296. https://doi.org/10.1038/nrm2354CrossRefPubMedPubMedCentral

44.

Liberti MV, Locasale JW (2016) The Warburg Effect: how does it benefit cancer cells? Trends Biochem Sci 41:211–218. https://doi.org/10.1016/j.tibs.2015.12.001CrossRefPubMedPubMedCentral

45.

Parks SK, Mueller-Klieser W, Pouysségur J (2020) Lactate and Acidity in the cancer microenvironment. Ann Rev Cancer Biol 4:141–158. https://doi.org/10.1146/annurev-cancerbio-030419-033556CrossRef

46.

Nakanishi-Matsui M, Matsumoto N (2022) V-ATPase a3 subunit in secretory lysosome trafficking in osteoclasts. Biol Pharm Bull 45:1426–1431. https://doi.org/10.1248/bpb.b22-00371CrossRefPubMed

47.

Maeda H, Kowada T, Kikuta J, Furuya M, Shirazaki M, Mizukami S, Ishii M, Kikuchi K (2016) Real-time intravital imaging of pH variation associated with osteoclast activity. Nat Chem Biol 12:579–585. https://doi.org/10.1038/nchembio.2096CrossRefPubMed

48.

Mantyh PW (2006) Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 7:797–809. https://doi.org/10.1038/nrn1914CrossRefPubMed

49.

Basbaum AI, Bautista DM, Scherrer G, Julius D (2009) Cellular and molecular mechanisms of pain. Cell 139:267–284. https://doi.org/10.1016/j.cell.2009.09.028CrossRefPubMedPubMedCentral

50.

Sun WH, Dai SP (2018) Tackling pain associated with rheumatoid arthritis: proton-sensing receptors. Adv Exp Med Biol 1099:49–64. https://doi.org/10.1007/978-981-13-1756-9_5CrossRefPubMed

51.

Louca Jounger S, Eriksson N, Lindskog H, Oscarsson A, Simonsson V, Ernberg M, Christidis N (2019) Repeated buffered acidic saline infusion in the human masseter muscle as a putative experimental pain model. Sci Rep 9:15474. https://doi.org/10.1038/s41598-019-51670-3CrossRefPubMedPubMedCentral

52.

Esposito MF, Malayil R, Hanes M, Deer T (2019) Unique characteristics of the dorsal root ganglion as a target for neuromodulation. Pain Med 20:S23-s30. https://doi.org/10.1093/pm/pnz012CrossRefPubMedPubMedCentral

53.

Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816–824. https://doi.org/10.1038/39807CrossRefPubMed

54.

Bujak JK, Kosmala D, Szopa IM, Majchrzak K, Bednarczyk P (2019) Inflammation, cancer and immunity-implication of TRPV1 channel. Front Oncol 9:1087. https://doi.org/10.3389/fonc.2019.01087CrossRefPubMedPubMedCentral

55.

Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313. https://doi.org/10.1126/science.288.5464.306CrossRefPubMed

56.

Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, Zamponi GW (2014) Calcium-permeable ion channels in pain signaling. Physiol Rev 94:81–140. https://doi.org/10.1152/physrev.00023.2013CrossRefPubMed

57.

Lieben L, Carmeliet G (2012) The involvement of TRP channels in Bone homeostasis. Front Endocrinol (Lausanne) 3:99. https://doi.org/10.3389/fendo.2012.00099CrossRefPubMed

58.

Li L, Chen C, Chiang C, Xiao T, Chen Y, Zhao Y, Zheng D (2021) The impact of TRPV1 on cancer pathogenesis and therapy: a systematic review. Int J Biol Sci 17:2034–2049. https://doi.org/10.7150/ijbs.59918CrossRefPubMedPubMedCentral

59.

Ghilardi JR, Röhrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, Mantyh PW (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126–3131. https://doi.org/10.1523/jneurosci.3815-04.2005CrossRefPubMedPubMedCentral

60.

Niiyama Y, Kawamata T, Yamamoto J, Omote K, Namiki A (2007) Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 148:560–572. https://doi.org/10.1016/j.neuroscience.2007.05.049CrossRefPubMed

61.

Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A (2009) SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth 102:251–258. https://doi.org/10.1093/bja/aen347CrossRefPubMed

62.

Xu Q, Zhang XM, Duan KZ, Gu XY, Han M, Liu BL, Zhao ZQ, Zhang YQ (2013) Peripheral TGF-β1 signaling is a critical event in bone cancer-induced hyperalgesia in rodents. J Neurosci 33:19099–19111. https://doi.org/10.1523/jneurosci.4852-12.2013CrossRefPubMedPubMedCentral

63.

Li Y, Cai J, Han Y, Xiao X, Meng XL, Su L, Liu FY, Xing GG, Wan Y (2014) Enhanced function of TRPV1 via up-regulation by insulin-like growth factor-1 in a rat model of bone cancer pain. Eur J Pain 18:774–784. https://doi.org/10.1002/j.1532-2149.2013.00420.xCrossRefPubMed

64.

Fang D, Kong LY, Cai J, Li S, Liu XD, Han JS, Xing GG (2015) Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model. Pain 156:1124–1144. https://doi.org/10.1097/j.pain.0000000000000158CrossRefPubMed

65.

Nagae M, Hiraga T, Wakabayashi H, Wang L, Iwata K, Yoneda T (2006) Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone 39:1107–1115. https://doi.org/10.1016/j.bone.2006.04.033CrossRefPubMed

66.

Shepherd AJ, Mickle AD, Kadunganattil S, Hu H, Mohapatra DP (2018) Parathyroid hormone-related peptide elicits peripheral TRPV1-dependent mechanical hypersensitivity. Front Cell Neurosci 12:38. https://doi.org/10.3389/fncel.2018.00038CrossRefPubMedPubMedCentral

67.

Riera CE, Huising MO, Follett P, Leblanc M, Halloran J, Van Andel R, de Magalhaes Filho CD, Merkwirth C, Dillin A (2014) TRPV1 pain receptors regulate longevity and metabolism by neuropeptide signaling. Cell 157:1023–1036. https://doi.org/10.1016/j.cell.2014.03.051CrossRefPubMed

68.

Lee CH, Chen CC (2018) Roles of ASICs in nociception and proprioception. Adv Exp Med Biol 1099:37–47. https://doi.org/10.1007/978-981-13-1756-9_4CrossRefPubMed

69.

Olson TH, Riedl MS, Vulchanova L, Ortiz-Gonzalez XR, Elde R (1998) An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. NeuroReport 9:1109–1113. https://doi.org/10.1097/00001756-199804200-00028CrossRefPubMed

70.

Jahr H, van Driel M, van Osch GJ, Weinans H, van Leeuwen JP (2005) Identification of acid-sensing ion channels in bone. Biochem Biophys Res Commun 337:349–354. https://doi.org/10.1016/j.bbrc.2005.09.054CrossRefPubMed

71.

Wemmie JA, Taugher RJ, Kreple CJ (2013) Acid-sensing ion channels in pain and disease. Nat Rev Neurosci 14:461–471. https://doi.org/10.1038/nrn3529CrossRefPubMedPubMedCentral

72.

Sluka KA, Price MP, Breese NM, Stucky CL, Wemmie JA, Welsh MJ (2003) Chronic hyperalgesia induced by repeated acid injections in muscle is abolished by the loss of ASIC3, but not ASIC1. Pain 106:229–239. https://doi.org/10.1016/s0304-3959(03)00269-0CrossRefPubMed

73.

Wu WL, Cheng CF, Sun WH, Wong CW, Chen CC (2012) Targeting ASIC3 for pain, anxiety, and insulin resistance. Pharmacol Ther 134:127–138. https://doi.org/10.1016/j.pharmthera.2011.12.009CrossRefPubMed

74.

Karczewski J, Spencer RH, Garsky VM, Liang A, Leitl MD, Cato MJ, Cook SP, Kane S, Urban MO (2010) Reversal of acid-induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2. Br J Pharmacol 161:950–960. https://doi.org/10.1111/j.1476-5381.2010.00918.xCrossRefPubMedPubMedCentral

75.

Yu Y, Chen Z, Li WG, Cao H, Feng EG, Yu F, Liu H, Jiang H, Xu TL (2010) A nonproton ligand sensor in the acid-sensing ion channel. Neuron 68:61–72. https://doi.org/10.1016/j.neuron.2010.09.001CrossRefPubMed

76.

Hsieh WS, Kung CC, Huang SL, Lin SC, Sun WH (2017) TDAG8, TRPV1, and ASIC3 involved in establishing hyperalgesic priming in experimental rheumatoid arthritis. Sci Rep 7:8870. https://doi.org/10.1038/s41598-017-09200-6CrossRefPubMedPubMedCentral

77.

Nagae M, Hiraga T, Yoneda T (2007) Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 25:99–104. https://doi.org/10.1007/s00774-006-0734-8CrossRefPubMed

78.

Qiu F, Wei X, Zhang S, Yuan W, Mi W (2014) Increased expression of acid-sensing ion channel 3 within dorsal root ganglia in a rat model of bone cancer pain. NeuroReport 25:887–893. https://doi.org/10.1097/wnr.0000000000000182CrossRefPubMed

79.

Qian HY, Zhou F, Wu R, Cao XJ, Zhu T, Yuan HD, Chen YN, Zhang PA (2021) Metformin attenuates bone cancer pain by reducing TRPV1 and ASIC3 expression. Front Pharmacol 12:713944. https://doi.org/10.3389/fphar.2021.713944CrossRefPubMedPubMedCentral

80.

Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N (2021) Treatment of multiple myeloma-related bone disease: recommendations from the bone working group of the international myeloma working group. Lancet Oncol 22:e119–e130. https://doi.org/10.1016/s1470-2045(20)30559-3CrossRefPubMed

81.

Mamet J, Baron A, Lazdunski M, Voilley N (2002) Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci 22:10662–10670. https://doi.org/10.1523/jneurosci.22-24-10662.2002CrossRefPubMedPubMedCentral

82.

Marra S, Ferru-Clément R, Breuil V, Delaunay A, Christin M, Friend V, Sebille S, Cognard C, Ferreira T, Roux C, Euller-Ziegler L, Noel J, Lingueglia E, Deval E (2016) Non-acidic activation of pain-related acid-sensing ion channel 3 by lipids. Embo J 35:414–428. https://doi.org/10.15252/embj.201592335CrossRefPubMedPubMedCentral

83.

Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D (2013) HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19:4046–4057. https://doi.org/10.1158/1078-0432.Ccr-13-0495CrossRefPubMedPubMedCentral

84.

Das N, Dewan V, Grace PM, Gunn RJ, Tamura R, Tzarum N, Watkins LR, Wilson IA, Yin H (2016) HMGB1 activates proinflammatory signaling via TLR5 leading to allodynia. Cell Rep 17:1128–1140. https://doi.org/10.1016/j.celrep.2016.09.076CrossRefPubMedPubMedCentral

85.

Sun S, Li H, Chen J, Qian Q (2017) Lactic acid: no longer an inert and end-product of glycolysis. Physiology (Bethesda) 32:453–463. https://doi.org/10.1152/physiol.00016.2017CrossRefPubMed

86.

Doherty JR, Cleveland JL (2013) Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123:3685–3692. https://doi.org/10.1172/jci69741CrossRefPubMedPubMedCentral

87.

Brooks GA (2018) The science and translation of lactate shuttle theory. Cell Metab 27:757–785. https://doi.org/10.1016/j.cmet.2018.03.008CrossRefPubMed

88.

Magistretti PJ, Allaman I (2018) Lactate in the brain: from metabolic end-product to signalling molecule. Nat Rev Neurosci 19:235–249. https://doi.org/10.1038/nrn.2018.19CrossRefPubMed

89.

Brown TP, Ganapathy V (2020) Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther 206:107451. https://doi.org/10.1016/j.pharmthera.2019.107451CrossRefPubMed

90.

Ishihara S, Hata K, Hirose K, Okui T, Toyosawa S, Uzawa N, Nishimura R, Yoneda T (2022) The lactate sensor GPR81 regulates glycolysis and tumor growth of breast cancer. Sci Rep 12:6261. https://doi.org/10.1038/s41598-022-10143-wCrossRefPubMedPubMedCentral

91.

Simatou A, Simatos G, Goulielmaki M, Spandidos DA, Baliou S, Zoumpourlis V (2020) Historical retrospective of the SRC oncogene and new perspectives (review). Mol Clin Oncol 13:21. https://doi.org/10.3892/mco.2020.2091CrossRefPubMedPubMedCentral

92.

Li Y, Bao Y, Zheng H, Qin Y, Hua B (2021) The nonreceptor protein tyrosine kinase Src participates in every step of cancer-induced bone pain. Biomed Pharmacother 141:111822. https://doi.org/10.1016/j.biopha.2021.111822CrossRefPubMed

93.

De Felice M, Lambert D, Holen I, Escott KJ, Andrew D (2016) Effects of Src-kinase inhibition in cancer-induced bone pain. Mol Pain. https://doi.org/10.1177/1744806916643725CrossRefPubMedPubMedCentral

94.

Appel CK, Gallego-Pedersen S, Andersen L, Blancheflor Kristensen S, Ding M, Falk S, Sayilekshmy M, Gabel-Jensen C, Heegaard AM (2017) The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain. Sci Rep 7:4792. https://doi.org/10.1038/s41598-017-05029-1CrossRefPubMedPubMedCentral

95.

Danson S, Mulvey MR, Turner L, Horsman J, Escott K, Coleman RE, Ahmedzai SH, Bennett MI, Andrew D (2019) An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. J Bone Oncol 19:100261. https://doi.org/10.1016/j.jbo.2019.100261CrossRefPubMedPubMedCentral

96.

Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM (2009) What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 103:1641–1646. https://doi.org/10.1111/j.1464-410X.2008.08283.xCrossRefPubMed

97.

Inoue T, Segawa T, Kamba T, Yoshimura K, Nakamura E, Nishiyama H, Ito N, Kamoto T, Habuchi T, Ogawa O (2009) Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 73:1104–1109. https://doi.org/10.1016/j.urology.2008.07.062CrossRefPubMed

98.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O’Sullivan JM (2016) Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 17:1306–1316. https://doi.org/10.1016/s1470-2045(16)30173-5CrossRefPubMed

99.

Koizumi M, Yoshimoto M, Kasumi F, Iwase T, Ogata E (2010) Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer 10:423. https://doi.org/10.1186/1471-2407-10-423CrossRefPubMedPubMedCentral

100.

Chen SH, Zhang BY, Zhou B, Zhu CZ, Sun LQ, Feng YJ (2019) Perineural invasion of cancer: a complex crosstalk between cells and molecules in the perineural niche. Am J Cancer Res 9:1–21PubMedPubMedCentral

101.

Delahunt B, Murray JD, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Matthews J, Oldmeadow C, Samaratunga H, Spry NA, Srigley JR, Hondermarck H, Denham JW (2020) Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR Trial. Histopathology 77:284–292. https://doi.org/10.1111/his.14107CrossRefPubMed

102.

Duraker N, Caynak ZC, Türköz K (2006) Perineural invasion has no prognostic value in patients with invasive breast carcinoma. Breast 15:629–634. https://doi.org/10.1016/j.breast.2005.12.003CrossRefPubMed

103.

Karak SG, Quatrano N, Buckley J, Ricci A Jr (2010) Prevalence and significance of perineural invasion in invasive breast carcinoma. Conn Med 74:17–21PubMed

104.

Gobbi H, Jensen RA, Simpson JF, Olson SJ, Page DL (2001) Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. Hum Pathol 32:785–790. https://doi.org/10.1053/hupa.2001.27637CrossRefPubMed

105.

Wang X, Lan H, Shen T, Gu P, Guo F, Lin X, Jin K (2015) Perineural invasion: a potential reason of hepatocellular carcinoma bone metastasis. Int J Clin Exp Med 8:5839–5846PubMedPubMedCentral

106.

Liu F, Zhao J, Xie J, Xie L, Zhu J, Cai S, Zheng H, Xu Y (2016) Prognostic risk factors in patients with bone metastasis from colorectal cancer. Tumour Biol. https://doi.org/10.1007/s13277-016-5465-4CrossRefPubMed

107.

Michalek J, Brychtova S, Pink R, Dvorak Z (2019) Prognostic and predictive markers for perineural and bone invasion of oral squamous cell carcinoma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 163:302–308. https://doi.org/10.5507/bp.2019.032CrossRefPubMed

108.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793–802. https://doi.org/10.1056/NEJMoa050434CrossRefPubMed

109.

Janni W, Vogl FD, Wiedswang G, Synnestvedt M, Fehm T, Jückstock J, Borgen E, Rack B, Braun S, Sommer H, Solomayer E, Pantel K, Nesland J, Friese K, Naume B (2011) Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse–a European pooled analysis. Clin Cancer Res 17:2967–2976. https://doi.org/10.1158/1078-0432.Ccr-10-2515CrossRefPubMed

110.

Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM (2013) Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 24:2515–2521. https://doi.org/10.1093/annonc/mdt223CrossRefPubMedPubMedCentral

111.

Yoneda T, Hiasa M, Okui T, Hata K (2021) Sensory nerves: a driver of the vicious cycle in bone metastasis? J Bone Oncol 30:100387. https://doi.org/10.1016/j.jbo.2021.100387CrossRefPubMedPubMedCentral

112.

Mogil JS (2019) The translatability of pain across species. Philos Trans R Soc Lond B Biol Sci 374:20190286. https://doi.org/10.1098/rstb.2019.0286CrossRefPubMedPubMedCentral

113.

Iftinca M, Defaye M, Altier C (2021) TRPV1-targeted drugs in development for human pain conditions. Drugs 81:7–27. https://doi.org/10.1007/s40265-020-01429-2CrossRefPubMed

Title: Cancer–nerve interplay in cancer progression and cancer-induced bone pain
Authors: Toshiyuki Yoneda
Masahiro Hiasa
Tatsuo Okui
Kenji Hata
Publication date: 30-01-2023
Publisher: Springer Nature Singapore
Keyword: Bone Metastasis
Published in: Journal of Bone and Mineral Metabolism / Issue 3/2023
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-023-01401-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Approaches

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2023

Management of cancer pain due to bone metastasis

Wnt signaling: a double-edged sword in protecting bone from cancer

Immunotherapy as a potential treatment approach for currently incurable bone metastasis

Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology

Factors associated with clonal hematopoiesis and interaction with marrow environment

Management of bone metastasis in prostate cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials